5002572025-01-012025-03-315002572025-03-315002572024-03-315002572024-04-012025-03-315002572025-01-012025-03-31in-capmkt:OtherExpenses1Member5002572025-01-012025-03-31in-capmkt:OtherExpenses2Member5002572024-04-012025-03-31in-capmkt:OtherExpenses1Member5002572024-04-012025-03-31in-capmkt:OtherExpenses2Member5002572025-01-012025-03-31in-capmkt:ReportableSegments1Member5002572025-01-012025-03-31in-capmkt:ReportableSegments2Member5002572025-01-012025-03-31in-capmkt:ReportableSegments8Member5002572025-01-012025-03-31in-capmkt:ReportableSegments9Member5002572024-04-012025-03-31in-capmkt:ReportableSegments1Member5002572024-04-012025-03-31in-capmkt:ReportableSegments2Member5002572024-04-012025-03-31in-capmkt:ReportableSegments8Member5002572024-04-012025-03-31in-capmkt:ReportableSegments9Member5002572025-01-012025-03-31in-capmkt:ReportableSegments1Member5002572025-01-012025-03-31in-capmkt:ReportableSegments2Member5002572025-01-012025-03-31in-capmkt:ReportableSegments8Member5002572025-01-012025-03-31in-capmkt:ReportableSegments9Member5002572024-04-012025-03-31in-capmkt:ReportableSegments1Member5002572024-04-012025-03-31in-capmkt:ReportableSegments2Member5002572024-04-012025-03-31in-capmkt:ReportableSegments8Member5002572024-04-012025-03-31in-capmkt:ReportableSegments9Member5002572025-01-012025-03-31in-capmkt:ReportableSegments1Member5002572025-03-31in-capmkt:ReportableSegments1Member5002572025-01-012025-03-31in-capmkt:ReportableSegments2Member5002572025-03-31in-capmkt:ReportableSegments2Member5002572025-01-012025-03-31in-capmkt:ReportableSegments8Member5002572025-03-31in-capmkt:ReportableSegments8Member5002572025-01-012025-03-31in-capmkt:ReportableSegments9Member5002572025-03-31in-capmkt:ReportableSegments9Member5002572025-01-012025-03-31in-capmkt:ReportableSegments1Member5002572025-03-31in-capmkt:ReportableSegments1Member5002572025-01-012025-03-31in-capmkt:ReportableSegments2Member5002572025-03-31in-capmkt:ReportableSegments2Member5002572025-01-012025-03-31in-capmkt:ReportableSegments8Member5002572025-03-31in-capmkt:ReportableSegments8Member5002572025-01-012025-03-31in-capmkt:ReportableSegments9Member5002572025-03-31in-capmkt:ReportableSegments9Member5002572025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15002572024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15002572025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2024-04-012025-03-312025-05-142025-04-29INRMillionsQuarterlyFourth quarterMulti segment2025-05-1417:00:002025-05-1419:55:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated56671300000569500000572408000001109460000057569000001050000010012500000891000000393180000016585100000482824000008958400000089584000002811100000-16765000001134600000078238000000000782380000023030000080541000007725200000986000007948600000105500000913200000216.9316.870016.9316.871. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on May 14 2025. <BR> <BR> 2. The Consolidated Financial Results include the financial results of the subsidiaries Lupin Pharmaceuticals Inc. U.S.A. Lupin Australia Pty Limited Australia Nanomi B.V. Netherlands Pharma Dynamics Proprietary Limited South Africa Hormosan Pharma GmbH Germany Multicare Pharmaceuticals Philippines Inc. Philippines Lupin Atlantis Holdings SA Switzerland Lupin Healthcare UK Limited U.K. Lupin Pharma Canada Limited Canada Generic Health Pty Limited Australia Bellwether Pharma Pty Limited Australia upto June 11 2023 Lupin Mexico S.A. de C.V. Mexico Lupin Philippines Inc. Philippines Lupin Diagnostics Limited India Generic Health SDN. BHD. Malaysia Lupin Inc. U.S.A. Laboratorios Grin S.A. de C.V. Mexico Medquimica Industria Farmaceutica LTDA Brazil Novel Laboratories Inc. U.S.A. Lupin Research Inc. U.S.A. Lupin Management Inc. U.S.A Lupin Europe GmbH Germany Lupin Biologics Limited India Lupin Oncology Inc. U.S.A Lupin Digital Health Limited India Avenue Coral Springs LLC U.S.A. Southern Cross Pharma Pty Ltd Australia Lupin Life Sciences Limited India w.e.f. July 17 2023 formerly known as Lupin Atharv Ability Limited India Lupin Manufacturing Solutions Limited India w.e.f. July 24 2023 Medisol S.A.S. France w.e.f. September 01 2023 Lymed S.A.S. France w.e.f. September 01 2023 till July 08 2024 Lupin Lanka Private Ltd. Sri Lanka w.e.f. August 05 2024 Lupin NZ Ltd. New Zealand w.e.f. August 08 2024 Lupinlife Consumer Healthcare Limited India w.e.f. March 8 2025 and a Trust Lupin Foundation India upto February 07 2025 and a joint venture YL Biologics Limited Japan. <BR> <BR> 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures. <BR> <BR> 4. The Board of Directors have at its meeting held on May 14 2025 recommended a dividend of Rs. 12 per equity share of the face value of Rs. 2 each aggregating Rs. 5478.8 million. The recommended dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting <BR> <BR> 5. During the quarter ended March 31 2025 330503 year to date 886137 equity shares of Rs. 2 each fully paid up were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs resulting in an increase in the paid up share capital by Rs. 0.7 million year to date Rs. 1.8 million and securities premium account by Rs. 334.0 million year to date Rs. 1082.3 million. <BR> <BR> 6. During the quarter ended December 31 2024 and year ended March 31 2025 the Group has made a provision of Rs. 856.1 million USD 10 million and Rs. 1441.2 million USD 17 million respectively towards ongoing disputes. <BR> <BR> 7. During the year ended March 31 2025 Lupin Limited and its subsidiary agreed to settle the dispute for an amount of USD 9.0 million Rs. 750.5 million in connection with the drug Glumetza® without admitting any liability for any wrongdoing with a view to avoid the costs and uncertainties of continued litigation. <BR> <BR> 8. During the year ended March 31 2024 Sales Income from operations includes milestone income of Rs. 2052.5 million USD 25.0 million from AbbVie for successful achievement of key milestone for its Phase 1 clinical stage MALT1 inhibitor program. <BR> <BR> 9. During the quarter and year ended March 31 2025 the Group has recognised an impairment charge of Rs. 1135.3 milion and Rs. 1209.0 milion respectively related certain tangible intangible assets and goodwill. During the quarter and year ended March 31 2024 the Group had recognised an impairment charge of Rs. 2012.5 milion related to intangibles assets including discontinued ANDAs and certain tangible assets. <BR> <BR> 12. The figures for the quarter ended March 31 2025 and March 31 2024 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter ended December 31 2024 and December 31 2023 respectively.2024-04-012025-03-31AuditedConsolidated22707900000019582000002290372000004457410000026426200000-25778000003964200000029487000001169260000066181400000188887200000401500000000401500000009906900000-28195000007087400000033062600000000033062600000-914700000321479000003281620000024640000031901900000246000000913200000217112180000071.9571.690071.9571.69Other Expenses16875600000Net (gain) / loss on foreign currency transactions-290500000Other Expenses66239300000Net (gain) / loss on foreign currency transactions-57900000514818000003554500000022326100000233856000001611900000027690000059580000003270000012934700000135632000005591000000227200000012406300000054763500000105911000005497100000015436900000159864000005020000033211000001003567000003463000001251930000016798580000000292048800000913200000171121800000172035000000908500000172943500000176623000000003159100000208214000004360800000226410000002045100000294914000003310420000085870000028722900000295816000008393400000710792000001140120000027318000004401700000089613900000001191053000002920488000001) Property, Plant and Equipment includes Right-of-use Assets of Rs. 4,483.2 mn. <BR> 2) Other Non-current Assets includes Non-current tax assets of Rs. 461.9 mn. <BR> 3) Other Non-current financial liabilities includes Lease liabilities of Rs. 2,642.7 mn. <BR> 4) Other Current Financial Liabilities includes lease liabilities of Rs. 1,068.5 mn.Pharmaceuticals56361100000Others315600000Less: Inter segment Assets0Less: Inter segment Liabilities0Pharmaceuticals226043100000Others1054500000Less: Inter segment Assets0Less: Inter segment Liabilities05667670000022709760000054000001860000056671300000227079000000Pharmaceuticals9322000000Others-363600000Less: Inter segment Assets0Less: Inter segment Liabilities0Pharmaceuticals41608100000Others-1458100000Less: Inter segment Assets0Less: Inter segment Liabilities0895840000040150000000895840000040150000000Pharmaceuticals292826100000Others2749200000Less: Inter segment Assets-3526500000Less: Inter segment Liabilities02920488000000292048800000Pharmaceuticals118208600000Others2966900000Less: Inter segment Assets0Less: Inter segment Liabilities-207020000011910530000001191053000002948700000-5412400000-78093000000-1898100000-5200000-2935000003028300000-257000000001120000001300000158100000116926000000-2508200000170200000863500000-411300000-38240000001359800000422500000-125000000-41690000001230000000-267902000001335980000000090604000000429940000004626000000000002935000001682425000000000000000000000012985000000-324070000-1601892000000398600000000002427740000001408900000365310000022952000000017318800000559928000005599280000983760000015436880000Items that will not be reclassified subsequently to profit or loss-178100000-178100000Items that will not be reclassified subsequently to profit or loss-233700000-233700000-64300000-79600000Items that will be reclassified subsequently to profit or loss344100000344100000Items that will be reclassified subsequently to profit or loss-760600000-76060000000230300000-914700000AuditedtrueBSR & Co. LLPtrue2025-07-31